Cargando…

Avastin and Lucentis: what do patients know? A prospective questionnaire survey

OBJECTIVES: To assess patients’ knowledge of their drug therapy for neovascular macular degeneration and to identify which aspects of the drug they considered most important if given the option of switching to an alternative drug. DESIGN: Prospective questionnaire survey. SETTING: Wolverhampton, Eng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manna, Avinash, Oyede, Oluwatoyin, Ning, Brigid, Yang, Yit, Narendran, Niro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767069/ https://www.ncbi.nlm.nih.gov/pubmed/24040500 http://dx.doi.org/10.1177/2042533313484146

Ejemplares similares

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
por: Merz, Patrick R., et al.
Publicado: (2018)

A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
por: Nagpal, Manish, et al.
Publicado: (2007)

Evaluation of patients’ experiences at different stages of the intravitreal injection procedure – what can be improved?
por: Tailor, Rajen, et al.
Publicado: (2011)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye
por: Raghuram, A, et al.
Publicado: (2007)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Systematic Review of Childhood Sedentary Behavior Questionnaires: What do We Know and What is Next?
por: Hidding, Lisan M., et al.
Publicado: (2016)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Pharmacokinetics of intravitreal bevacizumab (Avastin(®)) in rabbits
por: Sinapis, Christos I, et al.
Publicado: (2011)

Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
por: Zhao, Xuli, et al.
Publicado: (2022)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity
por: Shah, Parag K, et al.
Publicado: (2011)

Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion
por: Wang, Jing, et al.
Publicado: (2020)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro
por: Deissler, Heidrun L., et al.
Publicado: (2022)

Retracted: Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma
por: Mandal, Subrata, et al.
Publicado: (2011)

Using intravitreal bevacizumab (Avastin(®)) – Indian Scenario
por: Kumar, Atul, et al.
Publicado: (2017)

What do physicians know about homosexuality? Translation and adaptation of Knowledge about Homosexuality Questionnaire
por: Corrêa-Ribeiro, Renata, et al.
Publicado: (2018)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Experimental subjects do not know what we think they know
por: Field, Jared M., et al.
Publicado: (2020)

Health Statistics in Australia: What We Know and Do Not Know
por: Madden, Richard, et al.
Publicado: (2022)

The Burmese: What Do They Know of Medicine?
Publicado: (1876)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

What do patients know about healthcare-associated infections? What do they want to know? Ethical evaluation
por: Sahiner, Pervin
Publicado: (2023)

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
por: Strong, Stacey A., et al.
Publicado: (2016)

A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment
por: Andric, Marko, et al.
Publicado: (2013)

Cerebrospinal fluid circulation: What do we know and how do we know it?
por: Khasawneh, Ahmad H, et al.
Publicado: (2018)

Metal wear particles: What we know, what we do not know, and why
por: Billi, Fabrizio, et al.
Publicado: (2009)

Mechanisms of atrial fibrillation in athletes: what we know and what we do not know
por: Guasch, E., et al.
Publicado: (2018)

Identification of candidate protective variants for common diseases and evaluation of their protective potential
por: Butler, Joe M., et al.
Publicado: (2017)

Intravitreal Bevacizumab (Avastin) as an Adjuvant for the Treatment of Posterior Scleritis
por: Lim, Ji Won, et al.
Publicado: (2011)

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

What We Know and Do Not Know about Sex and Cardiac Disease
por: Konhilas, John P.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pgj66ukmo9l9tasuqhoeggsjff